Molecular Cancer Therapeutics

Table of Contents

November 2019 • Volume 18 • Issue 11

Highlights of This Issue 1897

REVIEWS

1899 ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications
Samantha A. Armstrong, Christopher W. Shultz, Ariana Azimi-Sadjadi, Jonathan R. Brody, and Michael J. Pishvaian

1909 Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
Nabil F. Saba, Zhuo Gerogia Chen, Missak Haigentz, Paolo Bossi, Alessandra Rinaldo, Juan P. Rodrigo, Antti A. Mäkitie, Robert P. Takes, Primoz Strojan, Jan B. Vermorken, and Alfio Ferlito

SMALL MOLECULE THERAPEUTICS

1916 First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer
Anna Capasso, Stacy M. Bagby, Kyrie L. Dailey, Naomi Currimjee, Betelehem W. Yacob, Anastasia Ionkina, Julie G. Frank, Deog Joong Kim, Christina George, Young B. Lee, Ely Benaim, Brian Gittleman, Sarah J. Hartman, Aik Choon Tan, Jihye Kim, Todd M. Pitts, S. Gail Eckhardt, John J. Tentler, and Jennifer R. Diamond

1926 Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Kerry A. Whalen, Brian H. White, James M. Quinn, Kristina Kriksciukaite, Rossitza Alargova, Tsun P. Au Yeung, Patrick Bazinet, Adam Brockman, Michelle M. DuPont, Haley Oller, James Gifford, Charles-Andre Lemelin, Patrick Lim Soo, Samantha Perino, Benoit Moreau, Gitanjali Sharma, Rajesh Shinde, Beata Sweryda-Krawiec, Mark T. Bilodeau, and Richard Wooster

1937 Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia

1947 Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer

1961 DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model
Gulzar Ahmad, Gerardo G. Mackenzie, James Egan, and Mansoor M. Amiji

1973 The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitro and In Vivo
Julie Kim, Chao Wang, Ainara Ruiz de Sahando, Hannah L. Cole, Timothy J. Huang, Jie Yang, Thomas D. Barnister, Vincent W. Yang, and Agnieszka B. Bialkowska

1985 KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage Strategy
Thomas Mühlenberg, Julia Ketzer, Michael C. Heinrich, Susanne Grunewald, Adrian Marino-Enriquez, Marcel Trautmann, Wolfgang Hartmann, Eva Wardelmann, Jürgen Treckmann, Karl Worm, Stefanie Bertram, Thomas Herold, Hans-Ulrich Schildhaus, Hanno Glimm, Albrecht Stenzinger, Benedikt Brors, Peter Horak, Peter Hohenberger, Stefan Fröhling, Jonathan A. Fletcher, and Sebastian Bauer

1997 Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor
Swadesh K. Das, Timothy P. Keegelman, Anjan K. Pradhan, Xue-Ning Shen, Praveen Bhoopathi, Sarmistha Talukdar, Santanu Maji, Devanand Sarkar, Luni Emdad, and Paul B. Fisher
<table>
<thead>
<tr>
<th>Year</th>
<th>Topic</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Anti-miRNA Oligonucleotide Therapy for Chondrosarcoma</td>
<td>Xiaojuan Sun, Yupeng Chen, Hongchuan Yu, Jason T. Machan, Ashna Alladin, Jose Ramirez, Ross Taliano, Jesse Hart, Qian Chen, and Richard M. Terek</td>
</tr>
<tr>
<td>2030</td>
<td>Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy</td>
<td>Massimo Masiero, Demin Li, Pat Whitehan, Carol Bentley, Jenny Greig, Tasneem Hassanali, Sarah Watts, Stephen Stibbling, Jenna Yates, Ellen Beating, Ji-Liang Li, Chandramoulie Chillakuri, Devon Sheppard, Sebastien Serres, Manuel Sarmiento-Soto, James Larkin, Nicola R. Sibson, Penny A. Handford, Adrian L. Harris, and Alison H. Banham</td>
</tr>
<tr>
<td>2043</td>
<td>U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer</td>
<td>Shigehiro Koganemaru, Yasutoshi Kuboki, Yoshikatsu Koga, Takashi Kojima, Mayumi Yamashita, Naoyuki Maeda, Takashi Kajari, Kenji Hironomi, Masahiro Yasunaga, Yasuhito Matsumura, and Yoshihiko Doi</td>
</tr>
<tr>
<td>2051</td>
<td>Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG3–Knockin Mice</td>
<td>Elena Burova, Ayun Hermann, Jie Dai, Erica Ullman, Gabor Halas, Terra Potocky, Seongwon Hong, Matt Liu, Omaira Allbritton, Amy Woodruff, Jenny Pei, Ashique Rafique, William Poueyminou, Joel Martin, Douglas MacDonald, William C. Olson, Andrew Murphy, Ella Ioffe, Gavin Thurston, and Markus Mohrs</td>
</tr>
<tr>
<td>2063</td>
<td>PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation</td>
<td>Anna R. Michmerhuizen, Andrea M. Pesch, Leah Moubadder, Benjamin C. Chandler, Kari Wilder-Romans, Meleah Cameron, Eric Olsen, Dafydd G. Thomas, Amanda Zhang, Nicole Hirsh, Cassandra L. Ritter, Meilan Liu, Shiyan Nyati, Lori J. Pierce, Reshma Jaggi, and Corey Speers</td>
</tr>
<tr>
<td>2074</td>
<td>Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model</td>
<td>Jun Wang, Darren K.W. Chan, Arindam Sen, Wen Wei Ma, and Robert M. Straubinger</td>
</tr>
<tr>
<td>2085</td>
<td>Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non–Small Cell Lung Carcinoma</td>
<td>Kexin Xu, Geng Sun, Min Li, Hongling Chen, Zuhaq Zhao, Xi Qi, Ping Li, Lin Xu, Wenbin Huang, and Xuerong Wang</td>
</tr>
<tr>
<td>2097</td>
<td>Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype</td>
<td>Yansong Bian, Yaroslav Teper, Lesley A. Mathews Griner, Taylor J. Aiken, Vivek Shukla, Rajarshi Guha, Paul Shinn, Hong-Wu Xin, Holger Pflicke, Astin S. Powers, Dandan Li, Jian-kang Jiang, Paresma Patel, Steven A. Rogers, Jeffrey Aubé, Marc Ferrer, Craig J. Thomas, and Udo Rudloff</td>
</tr>
<tr>
<td>2111</td>
<td>COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer</td>
<td>Syed Umbeher, Mudassir Meraj Banday, Azimbreem Jumroz, Adrian P. Mansini, Ashheed A. Ganaie, Marina G. Ferrari, Raihana Maqbool, Firdous H. Beigh, Paari Murugan, Colm Morrissey, Eva Corey, Badrinath R. Konety, and Mohammad Saleem</td>
</tr>
<tr>
<td>2124</td>
<td>Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma</td>
<td>Marta Baro, Cecilia Lopez-Sambrooks, Barbara A. Burtner, Mark A. Lemmon, and Joseph N. Contessa</td>
</tr>
</tbody>
</table>
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
Aïda Sampera, Francisco Javier Sánchez-Martín, Oriol Arpí, Laura Visa, Mar Iglesias, Silvia Menéndez, Élisabeth Gaye, Alba Dalmau, Sergi Clavé, Mariona Gelabert-Baldich, Thomas Tuxen Poulsen, Michael Kragh, Beatriz Bellosillo, Joan Albanell, Ana Rovira, and Clara Montagut

Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment
Deniz Cansen Kahraman, Tamer Kahraman, and Rengil Cetin-Atalay

eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer

Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier
Synnøve Nymark Aasen, Heidi Espedal, Christopher Florian Holte, Olivier Keunen, Tine Veronika Karlsen, Olav Tenstad, Zaynah Maherally, Hrvoje Miletic, Tuyen Hoang, Anne Vaag Eikeland, Habib Baghirov, Dag Erlend Olberg, Geoffrey John Pilkington, Gobinda Sarkar, Robert B. Jenkins, Terje Sundstrøm, Rolf Bjerkgård, and Frits Thorsen

Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
ABOUT THE COVER

Desmoplasia, hypovascularity, and hypoperfusion work in tandem to prevent antibody therapy of pancreatic adenocarcinoma. In order to disrupt the tumor-stroma interaction and alleviate these factors, Wang and colleagues designed a smoothened inhibitor of sonic hedgehog signaling (NVP-LDE225). In the patient-derived xenograft shown on the cover, NVP-LDE225 reduced the number of Ki67+ tumor cells (shown in green). Cell nuclei are counterstained in blue. Taken together, their results demonstrate that NVP-LDE225 dosage for five to ten days primes tumors for treatment with therapeutic antibodies such as cetuximab. Their results rationalize future clinical study of NVP-LDE225 in solid tumors. Read the full article on page 2074.
Molecular Cancer Therapeutics

18 (11)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/18/11

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/18/11.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.